Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
215
datasets available to search
ShareScore release 0.9.0
Dataset results
215 results for “cost analysis”
Database of the work "Sensitivity analysis as support for reliable life cycle cost evaluation an application on eleven nearly zero-energy buildings in Europe"
<p>This database reports the detailed results of the work "Sensitivity analysis as support for reliable life cycle cost evaluation an application on eleven nearly zero-energy buildings in Europe" published on the journal Sustainable Cities and Society.</p> <p>In particular, it includes the main sensitivity indices and life cycle cost values of eleven nZEB buildings across Europe as calculated within the H2020 project CRAVEzero (Cost Reduction and market Acceleration for Viable nearly zero-Energy buildings).</p> <p> </p>
Raw data and background analysis used in 'On optimising cost and value in eScience'
<p>Raw data and background analysis used in 'On optimising cost and value in eScience'.</p> <p>contains:</p> <ul> <li>LOFAR publications per year, including impact per publication (i.e. impact factor of journal at time of publications)</li> <li>instructive artificial example</li> <li>top 500 list, including computational efficiencies (Nov 2017 edition)</li> <li>impact of spectre and meltdown on UDP/IP packet receive performance (raw data and summary)</li> <li>Titan awards and prizes</li> </ul>
A cost-effectiveness analysis of second-generation antihistamine 1 receptor blockers and Japanese kampo shoseiryuto for treatment of perennial allergic rhinitis in outpatient settings in Japan
<p><strong><span>Background: </span></strong><span>Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are used commonly </span><span>for its</span><span> treatment, but it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese kampo shoseiryuto, which has been traditionally prescribed to treat PAR in Japan, remain poorly understood.</span></p> <p><strong><span>Objectives: </span></strong><span>This study aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer's perspective, using a base-case analysis.</span></p> <p><strong><span>Methods: </span></strong><span>The current study entailed identification of the most cost-effective of the six SGAs (</span><span>bepotastine 10 mg, cetirizine 10 mg, ebastine 10 mg, </span><span>epinastine 20</span><span> mg, loratadine 10 mg, and olopatadine 5 mg) and shoseiryuto, whose clinical effectiveness were evaluated using the overall improvement rate. </span><span>T</span><span>he time horizon</span><span> was 14 days. Costs were identified based on the Medical Fee Index in 2020.</span></p> <p><strong><span>Key findings: </span></strong><span>Overall, bepotastine 10 mg, cetirizine 10 mg, </span><span>ebastine </span><span>10 mg, and loratadine 10 mg were found to be cost-effective. Shoseiryuto was less cost-effective than ebastine 10 mg (dominated). Ebastine 10 mg was found to be the most cost-effective based on deterministic and probabilistic sensitivity analyses.</span></p> <p><strong><span>Conclusions: </span></strong><span>Ebastine 10 mg was found to be the most cost-effective treatment strategy for PAR among the agents evaluated in this study</span><span>. This insight might help </span><span>in creating an appropriate formulary for the treatment of PAR in hospitals and communities.</span></p>
A Cost-Utility Analysis of Oral Triptans for Migraine in an Adult Outpatient Setting in Japan
<p><strong><span>Objectives</span></strong><span><strong>. </strong>Pharmacoeconomic studies have not been performed frequently in Japan. This study attempted to clarify which oral triptans, including eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitrian, are cost-effective in treating migraine in an adult outpatient setting in Japan.</span></p> <p><strong><span>Methods</span></strong><span><strong>. </strong>A cost-utility analysis was conducted for healthcare payers. The population targeted was Japanese patients over the age of 18 who experienced migraines. A base-case model was prepared using probabilities from a network meta-analysis. Direct costs consisted of medical and drug costs (2017 version). Effectiveness was measured with the EQ-5D-3L questionnaire for adult patients with migraine. The duration of the study was 30 days.</span></p> <p><strong><span>Results</span></strong><span><strong>.</strong> The cost-utility analysis base-case scenario demonstrated that eletriptan, rizatriptan, and sumatriptan were cost-effective from the healthcare payers' perspective. Deterministic sensitivity analyses showed that the results were sensitive to the drug prices of three triptans. A probabilistic sensitivity analysis revealed that eletriptan, rizatriptan, and sumatriptan were acceptable because of their accessibility and the healthcare payer's willingness to pay for them (5,000,000 yen/quality-adjusted life-years) were 0.662, 0.172, and 0.075, respectively.</span></p> <p><strong><span>Conclusions</span><span>.</span> </strong><span>The results revealed that eletriptan, rizatriptan, and sumatriptan are cost-effective treat</span><span>ments</span><span> in Japan </span><span>for </span><span>migraine from a healthcare payer's perspective.</span></p>
Dominican Republic Mission Cost Analysis
ClinicalTrials.gov study NCT01872364. IPD Sharing: Not stated. Countries: 1. Publications: 42.
Cost-Effectiveness Analysis of a Virtual Reality-Assisted Hypnotherapy Program on Quality of Life in Patients with Chronic Low Back Pain: a Multicenter, Randomized, Prospective, Comparative, Open-Labe
ClinicalTrials.gov study NCT06698354. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Cost-Minimization Analysis After a Targeted Intervention for EGD and Colonoscopy
ClinicalTrials.gov study NCT02328001. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis
ClinicalTrials.gov study NCT01720238. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cost Utility Analysis of HD and CAPD in Ministry of Health Dialysis Centres, Malaysia
ClinicalTrials.gov study NCT02862717. IPD Sharing: UNDECIDED. Countries: 1. Publications: 9.
Cost-effectiveness Analysis Between Biosynthetic and Biological Parietal Prostheses
ClinicalTrials.gov study NCT03590184. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules
ClinicalTrials.gov study NCT02398721. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure.
ClinicalTrials.gov study NCT03758105. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pediatric Femur Fractures: Functional Bracing vs Spica Casting - Outcomes and Cost Analysis
ClinicalTrials.gov study NCT06569199. IPD Sharing: NO. Countries: 1. Publications: 1.
Ambulatory Laparoscopic Inguinal Hernioplasty: Feasibility and Cost Analysis
ClinicalTrials.gov study NCT04504461. IPD Sharing: UNDECIDED. Countries: 1. Publications: 6.
Mandibular Overdenture Retained by 1 or 2 Implants: a Cost-effectiveness Analysis
ClinicalTrials.gov study NCT03691285. IPD Sharing: NO. Countries: 1. Publications: 0.
Cost-effective Analysis of Two Approximation Devices in Closure of Gastrointestinal Defects
ClinicalTrials.gov study NCT05163665. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer: An Analysis Using NHIS Database and K-PaC Registry Focusing on Liposomal Irinotecan
ClinicalTrials.gov study NCT04984174. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Clinical Evaluation and Cost-effectiveness Analysis of 3D Digital Surgery in Traumatology
ClinicalTrials.gov study NCT06603831. IPD Sharing: YES. Countries: 1. Publications: 22.
Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening
ClinicalTrials.gov study NCT02038283. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Psychosomatic Therapy, Feasibility and Cost Analysis
ClinicalTrials.gov study NCT01935258. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.